In connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small molecules and vaccine candidates. This information concerns the efficacy...
Read MoreKancera reports that the company has registered a patent application (EP14167988.6) for new compounds against cancer that selectively inhibit the enzyme HDAC6. The new patent application is based on the ability of HDAC6 inhibitors to influence mechanisms both inside...
Read MoreIn 2013, a collaboration was initiated between Kancera and Professor Thomas Helleday at the Science for Life Laboratory, Karolinska Institutet , in order to advance unique research on metabolism of cancer and PFKFB3 as a target for drug development....
Read MoreKancera reports that the company is initiating the development of a vaccine directed against ROR. This initiative is motivated by the residual disease in the form of a small number of cancer cells that remain in some patients despite...
Read MoreKancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe side effects, due to poor selectivity, have limited the...
Read MoreKancera together with international research groups in the project A-PARADDISE has been awarded a grant from the European Union Seventh Framework Programme to develop drugs to combat severe parasitic diseases including malaria, schistosomiasis, leishmaniasis and Chagas disease. The total...
Read MoreKancera reports progress in the development of a ROR-inhibiting cancer drug. The compound KAN0439365 is effective against cancer cells from patients and show good metabolic stability in human liver cells and blood. KAN0439365 is the first in a new...
Read MoreKancera reports results from a collaboration with Professor Håkan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer is ROR-1 dependent. The results provide further support for...
Read MoreKancera reports that the company's first generation of PFKFB3 inhibiting compounds reduces growth of pancreatic cancer in a pre-clinical animal study.
Read MoreNEW YORK and STOCKHOLM, Oct. 04, 2012 - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, a subsidiary to Kancera AB ...
Read More